Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

Medicin og biovidenskab

• Adipose Tissue 4%
• Biological Phenomena 5%
• Biomarkers 3%
• Blood Glucose 4%
• Cause of Death 4%
• Dyspnea 5%
• empagliflozin 89%
• Fibrosis 8%
• Heart Failure 42%
• Hospitalization 8%
• Inflammation 6%
• Kidney 3%
• Morbidity 34%
• Mortality 29%
• Placebos 3%
• Pressure 3%
• Sodium 9%
• Sodium-Glucose Transporter 2 100%
• Sodium-Glucose Transporter 2 Inhibitors 16%
• Stroke Volume 5%
• Symporters 78%
• Theoretical Models 4%
• Therapeutics 0%
• Treatment Failure 5%
• Type 2 Diabetes Mellitus 4%
• Vascular Stiffness 6%